228 related articles for article (PubMed ID: 15587107)
1. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
3. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
4. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.
Reidenbach C; Schwinger RH; Steinritz D; Kehe K; Thiermann H; Klotz T; Sommer F; Bloch W; Brixius K
Life Sci; 2007 Jun; 80(26):2421-7. PubMed ID: 17512554
[TBL] [Abstract][Full Text] [Related]
6. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
8. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
[TBL] [Abstract][Full Text] [Related]
11. Evolving mechanisms of action of beta blockers: focus on nebivolol.
Mason RP; Giles TD; Sowers JR
J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation.
Maffei A; Di Pardo A; Carangi R; Carullo P; Poulet R; Gentile MT; Vecchione C; Lembo G
Hypertension; 2007 Oct; 50(4):652-6. PubMed ID: 17664392
[TBL] [Abstract][Full Text] [Related]
13. ENOS is not activated by nebivolol in human failing myocardium.
Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
[TBL] [Abstract][Full Text] [Related]
14. Beta-blockers in the management of hypertension: focus on nebivolol.
Wojciechowski D; Papademetriou V
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
[TBL] [Abstract][Full Text] [Related]
15. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
Prisant LM
J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
[TBL] [Abstract][Full Text] [Related]
17. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
18. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
20. Signalling transduction pathways implicated in Nebivolol-induced NO production in endothelial cells.
Kadi A; Moby V; de Isla N; Lacolley P; Menu P; Stoltz JF
Biomed Mater Eng; 2008; 18(4-5):303-7. PubMed ID: 19065039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
